← Trials/Trial dossier/NCT01779362

RISE Adult

CompletedPhase 3Results posted

RISE Adult Medication Study

Restoring Insulin Secretion Adult Medication Study

Lead sponsor

RISE Study Group

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

4

Recruiting sites

Enrollment

267

actual

Study population

Obesity / overweight, Prediabetes / glucose intolerance, Type 2 diabetes

Key I/E criteria

BMI ≥25HbA1c ≤7%

Primary endpoints

SS-cell ResponseHOMA-IR (insulin sensitivity)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01779362
Org study IDRISE Adult
Secondary ID5U01DK094406-02

Timeline

Milestones

Study first posted2013-01-30estimated
Last update posted2023-05-11actual
Results first posted2023-05-11actual
Study start2013-04 (month precision)
Primary completion2019-02actual (month precision)
Study completion2019-08actual (month precision)

Assets

Investigational agents

Study populations

Who this study enrolls

Obesity / overweightPrediabetes / glucose intoleranceType 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

1. Fasting plasma glucose 95-125 mg/dl plus 2-hour glucose ≥140 mg/dl on 75 gm OGTT plus HbA1c ≤7.0%. There is no upper limit for the 2-hour glucose on OGTT.

2. Age 20-65 years

3. Body mass index (BMI) ≥25 kg/m2 but ≤50 kg/m2

4. Self-reported diabetes <1 year in duration

5. Drug naïve (no prior to oral glucose lowering agent(s), insulin or other injectable glucose lowering agents)

Exclusion criteria

1. Underlying disease likely to limit life span and/or increase risk of intervention or an underlying condition that is likely to limit ability to participate in outcomes assessment

2. An underlying disease that affects glucose metabolism other than type 2 diabetes

3. Taking medications that affect glucose metabolism, or has an underlying condition that is likely to require such medications

4. Active infections

5. Renal disease (serum creatinine >1.4 mg/dl for men; >1.3 mg/dl for women) or serum potassium abnormality (<3.4 or >5.5 mmol/l)

6. Anemia (hemoglobin <11 g/dl in women, <12 g/dl in men) or known coagulopathy

7. Cardiovascular disease, including uncontrolled hypertension. Participants must be able to safely tolerate administration of intravenous fluids required during clamp studies.

8. History of conditions that may be precipitated or exacerbated by a study drug:

1. Pancreatitis

2. Serum alanine transaminase (ALT) more than 3 times the upper limit of normal

3. Excessive alcohol intake

4. Suboptimally treated thyroid disease

5. Medullary carcinoma of the thyroid or MEN-2 (in participant or a family history)

6. Hypertriglyceridemia (>400 mg/dl despite treatment)

9. Conditions or behaviors likely to affect the conduct of the RISE Study

1. Unable or unwilling to give informed consent

2. Unable to adequately communicate with clinic staff

3. Another household member is a participant or staff member in RISE

4. Current, recent or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in RISE

5. Weight loss of >5% in past three months for any reason other than post-partum weight loss. Participants taking weight loss drugs or using preparations taken for intended weight loss are excluded.

6. Likely to move away from participating clinics in next two years

7. Women of childbearing potential who are unwilling to use adequate contraception

8. Current (or anticipated) pregnancy and lactation.

9. Major psychiatric disorder that, in the opinion of clinic staff, would impede the conduct of RISE

10. Additional conditions may serve as criteria for exclusion at the discretion of the local site.

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

8 endpoints
Primary/registry result/low confidence

ß-cell Response Measured by Hyperglycemic Clamp

Time frame:3-months after medication washout (Month 15)

descriptive

Posted result

GroupValue (geometric_mean), nmol/L95% CI
Metformin AloneSteady State C-peptide3.651.94 – 6.87
ACPRmax4.612.00 – 10.66
Glargine Followed by MetforminSteady State C-peptide3.581.68 – 8.33
ACPRmax4.321.58 – 11.80
PlaceboSteady State C-peptide3.601.72 – 7.53
ACPRmax4.451.56 – 12.71
Liraglutide + MetforminSteady State C-peptide3.731.87 – 7.44
ACPRmax4.582.21 – 9.48
p>0.05Regression, Linear
Primary/registry result

Insulin Sensitivity, M/I

Time frame:3-months after a medication washout

HOMA-IR (insulin sensitivity)

descriptive, improvement

Posted result

GroupValue (geometric_mean), x 10-5 mmol/kg/min per pmol/L95% CI
Metformin Alone3.530.67 – 18.49
Glargine Followed by Metformin3.380.61 – 18.84
Placebo3.630.95 – 13.84
Liraglutide + Metformin3.490.90 – 13.54
p>0.05Regression, Linear
Primary/protocol endpoint

ß-cell Response Measured by Hyperglycemic Clamp

Time frame:3-months after medication washout (Month 15)

descriptive

Primary/protocol endpoint

Insulin Sensitivity, M/I

Time frame:3-months after a medication washout

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Secondary/registry result/low confidence

ACPRg

Time frame:3-months after a medication washout

descriptive

Posted result

GroupValue (geometric_mean), nmol/L95% CI
Metformin Alone1.680.84 – 3.34
Glargine Followed by Metformin1.680.91 – 3.09
Placebo1.680.86 – 3.26
Liraglutide + Metformin1.680.99 – 2.83
p>0.05Regression, Linear
Secondary/registry result/low confidence

ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12

Time frame:Secondary analysis was on all participants with a Month 12 visit.

descriptive

Posted result

GroupValue (geometric_mean), nmol/L95% CI
Metformin AloneACRPg1.931.09 – 3.40
Steady State C-peptide11.75.6 – 24.3
ACRPmax13.45.9 – 30.7
Glargine Followed by MetforminACRPg1.881.06 – 3.22
Steady State C-peptide11.65.6 – 24.3
ACRPmax14.15.8 – 34.3
PlaceboACRPg1.690.89 – 3.22
Steady State C-peptide10.85.1 – 22.7
ACRPmax13.65.1 – 36.1
Liraglutide + MetforminACRPg2.681.28 – 5.60
Steady State C-peptide21.29.3 – 48.3
ACRPmax10.13.5 – 28.5
p<0.001ANOVA

Analyses were completed on a log scale and re-exponentiated for display.

Secondary/protocol endpoint/low confidence

ACPRg

Time frame:3-months after a medication washout

change from baseline, improvement

Secondary/protocol endpoint/low confidence

ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12

Time frame:Secondary analysis was on all participants with a Month 12 visit.

descriptive

Publications (15)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.